scispace - formally typeset
G

Gerjan Navis

Researcher at University Medical Center Groningen

Publications -  702
Citations -  43890

Gerjan Navis is an academic researcher from University Medical Center Groningen. The author has contributed to research in topics: Renal function & Population. The author has an hindex of 88, co-authored 652 publications receiving 37714 citations. Previous affiliations of Gerjan Navis include Istituto Superiore di Sanità & University of Groningen.

Papers
More filters
Journal ArticleDOI

Tissue distribution of ACE2 protein, the functional receptor for SARS coronavirus. A first step in understanding SARS pathogenesis

TL;DR: ACE2 is abundantly present in humans in the epithelia of the lung and small intestine, which might provide possible routes of entry for the SARS‐CoV.
Journal ArticleDOI

Genetic variants in novel pathways influence blood pressure and cardiovascular disease risk

Georg Ehret, +391 more
- 06 Oct 2011 - 
TL;DR: A genetic risk score based on 29 genome-wide significant variants was associated with hypertension, left ventricular wall thickness, stroke and coronary artery disease, but not kidney disease or kidney function, and these findings suggest potential novel therapeutic pathways for cardiovascular disease prevention.
Journal ArticleDOI

Genome-wide association study identifies eight loci associated with blood pressure

Christopher Newton-Cheh, +362 more
- 01 Jun 2009 - 
TL;DR: In this paper, the association between systolic or diastolic blood pressure and common variants in eight regions near the CYP17A1 (P = 7 × 10(-24)), CYP1A2(P = 1 × 10-23), FGF5 (P=1 × 10 -21), SH2B3(P= 3 × 10−18), MTHFR(MTHFR), c10orf107(P), ZNF652(ZNF652), PLCD3 (P,P = 5 × 10 −9),
Journal ArticleDOI

The interleukin-6 receptor as a target for prevention of coronary heart disease: a mendelian randomisation analysis.

Daniel I. Swerdlow, +115 more
- 31 Mar 2012 - 
TL;DR: IL6R blockade could provide a novel therapeutic approach to prevention of coronary heart disease that warrants testing in suitably powered randomised trials and could help to validate and prioritise novel drug targets or to repurpose existing agents and targets for new therapeutic uses.
Journal ArticleDOI

Increased Central Venous Pressure Is Associated With Impaired Renal Function and Mortality in a Broad Spectrum of Patients With Cardiovascular Disease

TL;DR: Investigation of the relationship between increased central venous pressure, renal function, and mortality in a broad spectrum of cardiovascular patients found that CVP was an independent predictor of reduced survival and independently related to all-cause mortality.